In India, weight loss medications like Wegovy, Monjaro, and Ozempic, primarily used for managing diabetes, have become notoriously expensive, often costing between ₹9,000 to ₹28,000 per month. However, due to the expiration of the patent for Semaglutide on March 20, these prices are expected to fall drastically. This patent cliff will enable Indian pharmaceutical companies to introduce generic versions, significantly reducing the financial barrier for individuals seeking effective weight loss options.

Experts predict that post-March 21, the monthly cost of these weight loss injections could drop to between ₹3,000 to ₹4,000, allowing broader access to these treatments. This price reduction is attributed to the nature of generics, which do not require the extensive research and development expenses that branded medications incur. The implications of this change are substantial, as it could lead to a rise in demand for these medications and a shift in how obesity and diabetes are managed in India.

The anticipated decrease in price not only highlights the impact of patent laws on drug affordability but also raises questions about market competition and consumer health access. With the potential for greater availability of affordable weight loss treatments, it will be crucial for consumers to receive proper guidance on their use and ensure that this surge in accessibility translates into improved health outcomes.